Up to three million people in the UK are thought to have Restless Legs Syndrome (RLS), a condition which is more common in women than men. (Source: the Mail online | Health)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

(Source: Psychiatry and Clinical Neurosciences)

In conclusion, the question remains whether the included patients actually had OSA (even mild) or another sleep disorder (such as RLS or PLMD) that may result in significant alterations in sleep macro- and microarchitecture. The increased arousal index (after the exclusion of spontaneous arousals) in the initial and the follow up PSGs seems to suggest the latter. (Source: Sleep Medicine)

Abstract: Background: Despite being frequently described in patients with end-stage renal disease (ESRD), clinical characteristics and comorbidities in association with restless legs syndrome (RLS) are still to be confirmed.Objectives: The aim of this study was to investigate clinical factors associated with RLS in ESRD patients in hemodialysis.Methods: This is a cross-sectional study of 400 patients on hemodialysis, evaluating RLS, clinical features and other sleep abnormalities.Results: Out of 400, 86 patients presented RLS (21.5%; mean age 48.8±13.8y), being more frequent in females (p (Source: Sleep Medicine)

Metastatic Colorectal Cancer Aspirin Use with Risk of Ulcer Restless Legs Syndrome (RLS) (Source: The Doctors Lounge - Health News)

(Source: Reactions)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Authors: Calhoun DA, Harding SM Ambulatory BP studies indicate that even small increases in BP, particularly nighttime BP levels, are associated with significant increases in cardiovascular morbidity and mortality. Accordingly, sleep-related diseases that induce increases in BP would be anticipated to substantially affect cardiovascular risk. Both sleep deprivation and insomnia have been linked to increases in incidence and prevalence of hypertension. Likewise, sleep disruption attributable to restless legs syndrome increases the likelihood of having hypertension. Observational studies demonstrate a strong correlation between the severity of obstructive sleep apnea (OSA) and the risk and severity of hypertension, whereas prospective studies of patients with OSA demonstrate a positive r...

Among patients with multiple sclerosis (MS), fatigue is the most commonly reported symptom, and one of the most debilitating. Despite its high prevalence and significant impact, fatigue is still poorly understood and often under-emphasized because of its complexity and subjective nature. In recent years, an abundance of literature from specialists in sleep medicine, neurology, psychiatry, psychology, physical medicine and rehabilitation, and radiology have shed light on the potential causes, impact, and treatment of MS-related fatigue. Though such a diversity of contributions clearly has advantages, few recent articles have attempted to synthesize this literature, and existing overviews have focused primarily on potential causes of fatigue rather than clinical evaluation or treatment. The...

Abstract (Source: Movement Disorders)

UCB announced the results of a 6-month, randomized, double-blind, placebo-controlled clinical study, published in the journal Movement Disorders, showing that Neupro® (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of Restless Legs Syndrome (RLS). The study also showed high rates of complete remission seen with rotigotine 2 mg or 3 mg/24 hours... (Source: Health News from Medical News Today)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments High rates of ... BiopharmaceuticalsUCB, Neupro, rotigotine, Restless Legs Syndrome (Source: HSMN NewsFeed)MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)

Neupro® (rotigotine transdermal system) study conducted in the U.S. published in the journal Movement Disorders - Study represented the longest double-blind treatment period maintained in the U.S. for the evaluation of RLS treatments - High... (Source: Drugs.com - Clinical Trials)